This CONTINGENT VALUE RIGHTS
AGREEMENT (this “Agreement”), dated as of [ • ], is entered into by and between Passage Bio, Inc., a Delaware corporation (“Passage”), and [ • ], a [ • ], as initial Rights Agent (as defined herein).
PREAMBLE
WHEREAS, Passage, Peregrine Merger Sub, Inc., a Delaware corporation and
a wholly-owned subsidiary of Passage (“Merger Sub”), and Remix Therapeutics, Inc., a Delaware corporation (the “Company”), have entered into an Agreement and Plan of Merger, dated as of June 24, 2026 (as it may be amended,
supplemented or otherwise modified from time to time pursuant to the terms thereof, the “Merger Agreement”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the
Merger as a wholly-owned subsidiary of Passage (the “Surviving Corporation”);
WHEREAS, in connection with the Merger Agreement, Passage has agreed to
provide to the Holders (as defined herein) certain contingent value rights as hereinafter described;
WHEREAS, the parties to this Agreement have done all things necessary to
make the contingent value rights, when issued pursuant to this Agreement, the valid obligations of Passage and to make this Agreement a valid and binding agreement of Passage, in accordance with its terms; and
NOW, THEREFORE, in consideration of the premises and the consummation of
the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows:
ARTICLE 1
DEFINITIONS
|
Section 1.1
|
Definitions. Capitalized terms used but not otherwise defined herein have the
meanings ascribed thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows:
|
“Acting Holders” means, at any time, the registered Holders of
more than thirty-five percent (35%) of the total number of CVRs outstanding at such time, as set forth on the CVR Register.
“Affiliate” means, with respect to any Person, any other Person
directly or indirectly controlling, controlled by, or under common control with such other Person. For purposes of this definition, “control” when used with respect to any Person means the power to direct the management and policies of
such Person, directly or indirectly, whether through the ownership of voting securities or partnership or other ownership interests, by contract or otherwise, and the terms “controlling” and “controlled” have correlative meanings.
“Catalent” means Catalent Pharma Solutions, LLC.
“Catalent Storage Costs” means any documented out-of-pocket
costs and expenses paid or payable by Passage or any of its Subsidiaries to Catalent for the storage and maintenance of MLD product supply materials.
“Closing” means the closing of the Merger.
“Closing Date” means the date on which the Closing actually takes
place.
“Commercially Reasonable Efforts” means, with respect to the
collection of Legacy Asset Payments, carrying out those obligations and tasks in a good faith and diligent manner; taking into account all commercial and other relevant factors that Passage, exercising good faith, would normally take into
account with a collection of amounts receivable from a commercial counterparty, provided that, notwithstanding the foregoing, such level of efforts and resources shall not require Passage
to advance, expend or commit any funds (other than de minimis administrative costs and the GM1 2027 License Payment) in connection with the collection of any Legacy Asset Payments; provided, further, that such level of efforts and resources shall be determined without taking into account the CVR Payment payable in accordance
with, and subject to, the terms hereof.
“CVR” means a contingent contractual right of Holders to receive
CVR Payments under this Agreement.
“CVR Payment” means, with respect to each Legacy Asset Payment,
the CVR Proceeds attributable to such Legacy Asset Payment.
“CVR Payment Period” means an annual period (or portion thereof)
beginning on the Closing Date and ending on December 31 of any given calendar year during the CVR Period; provided that if the last CVR Payment Period would end subsequent to the expiration
of the CVR Period, such CVR Payment Period will end on the last day of the CVR Period.